---
title: "China Southern Fund's Hong Kong Connect Innovative Drug ETF has attracted significant attention from investors, with a concentrated release of favorable news for innovative drugs. Short-term corrections do not change its long-term allocation value"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278442136.md"
description: "As of March 9, 2026, the Hong Kong Stock Connect Innovative Drug ETF China Southern (159297) had a turnover of 6.69%, with a transaction volume of 105 million yuan, while the tracked CNI Hong Kong Connect Innovative Drug Index fell by 1.7%. Soochow Securities pointed out that the Two Sessions have for the first time listed innovative drugs as an \"emerging pillar industry\" and proposed to accelerate the development of commercial insurance to promote the high-quality development of innovative drugs. The biopharmaceutical industry has entered a strategic pillar stage, and the medium- to long-term allocation value of the innovative drug sector has attracted attention, making it a good time for investment"
datetime: "2026-03-09T10:24:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278442136.md)
  - [en](https://longbridge.com/en/news/278442136.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278442136.md)
---

# China Southern Fund's Hong Kong Connect Innovative Drug ETF has attracted significant attention from investors, with a concentrated release of favorable news for innovative drugs. Short-term corrections do not change its long-term allocation value

As of the close on March 9, 2026, the South China (159297) Hong Kong Stock Connect Innovative Drug ETF had a turnover of 6.69%, with a transaction volume of 105 million yuan, while the tracked index, the China National Securities Hong Kong Stock Connect Innovative Drug Index, fell by 1.7%.

Dongxing Securities pointed out that the two sessions have for the first time listed innovative drugs as an "emerging pillar industry," proposing to accelerate the development of commercial insurance and promote the high-quality development of innovative drugs. This year's government work report from the national two sessions clearly positions biomedicine as an "emerging pillar industry," marking a new stage for the biomedicine industry as it transitions from a cultivation period to a strategic pillar and economic growth engine. Regarding commercial insurance, the work report proposed to accelerate the development of commercial health insurance. As of March 6, 2026, the total package for China's innovative drug overseas business development (BD) has reached 56.8 billion USD, with an upfront payment of 3.3 billion USD. The total package is equivalent to 41% of the entire year of 2025, exceeding the full-year level of 2024, and the upfront payment amount is equivalent to 46% of the entire year of 2025. The institution remains optimistic about the medium- to long-term allocation value of the innovative drug sector.

The South China (159297) Hong Kong Stock Connect Innovative Drug ETF closely tracks the China National Securities Hong Kong Stock Connect Innovative Drug Index, which aims to reflect the operational characteristics of listed companies in the innovative drug field within the scope of the Hong Kong Stock Connect. The top ten weighted stocks in the index are CSPC Pharmaceutical Group, Innovent Biologics, BeiGene, China Biologic Products, CanSino Biologics, Hansoh Pharmaceutical, 3SBio, Kelun-Biotech, Kangzhong Pharmaceutical, and United Pharmaceutical.

The South China (159297) Hong Kong Stock Connect Innovative Drug ETF serves as a convenient tool for investing in the Hong Kong innovative drug sector and is currently in a configuration window of "upward fundamentals, relatively low valuations, and approaching catalysts," with clear industry trends and significant long-term investment value.

### Related Stocks

- [159297.CN](https://longbridge.com/en/quote/159297.CN.md)
- [520700.CN](https://longbridge.com/en/quote/520700.CN.md)

## Related News & Research

- [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md)
- [Keep Your Portfolio Safe With This Low-Volatility ETF](https://longbridge.com/en/news/286604877.md)
- [This ETF Is Flying High Again. Here's How to Tell If It Will Continue.](https://longbridge.com/en/news/285754960.md)
- [1 Rapidly Deteriorating ETF Screams That ‘Shop ‘Til You Drop’ Americans Have All But Keeled Over](https://longbridge.com/en/news/286429552.md)
- [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md)